Human and Veterinary Vaccinology

Course summary

Human and Veterinary Vaccinology



Overview

The Human and Veterinary Vaccinology course is a five-day course which covers all aspects of vaccinology.

The course is designed as a stand-alone module or can be taken as an add-on to the Clinical Vaccine Development and Biomanufacturing module.

The course includes contributions from world-leading experts. In the past these have included:

  • Prof David Salisbury (Director of Immunisation, UK Department of Health)
  • Dr Vasee Moorthy (Department of Immunisation, Vaccines & Biologicals, WHO - World Health Organisation)
  • Prof Andrew Pollard (Director, Oxford Vaccine Group, University of Oxford)
  • Dr Laura Martin (Development Project Leader, Novartis Vaccines Institute for Global Health)
  • Prof Adrian Hill (Director, Jenner Institute, University of Oxford)
  • Prof Paul Fine (Professor of Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine)
  • Prof Andy Peters (Interim Chief Executive Officer, GALVmed)

The Programme provides state-of-the-art teaching in both human and veterinary vaccinology, drawing on the experience of Oxford University, the world-renowned Jenner Institute based in Oxford, The Pirbright Institute (formerly the Institute for Animal Health - IAH) and our partners in industry.

 

Follow us on Twitter@Oxford_Biosci

Vaccinology is a cross-disciplinary subject and the most exciting developments in vaccinology have occurred when people from diverse research, business and medical backgrounds have used their skills to collectively tackle problems in vaccine design, manufacture and distribution.

Our course participants will therefore reflect the diversity of the subject and be from business, academic, clinical and veterinary backgrounds. The course will be of particular interest to research scientists, programme managers, clinical trial coordinators, nurses, physicians and veterinarians. The course will be accessible to people already working in the field or to those who wish to enter the field.

----------------------------------------------------------------

What people say about the course...

 

Well structured, excellent lectures and course materials
- Claudio Busato, Scientific Administrator, Development and Evaluation of Veterinary Medicine's sector, European Medicines Agency

This was an OUTSTANDING week in Oxford. I learned a lot of new stuff and consolidated a lot of other knowledge as well
- Anonymous

Excellent! Programme fulfilled my need to be more scientific with immunology concepts. Lectures were very effective and delivered in a very practical way
- Cinzia Marano, Senior Epidemiologist, GlaxoSmithKline Biologicals

----------------------------------------------------------------

There are two courses currently in the Vaccinology Programme (including this course):

Programme details

Day 1

  • 09.00 – 9.15: Welcome and overview to the week
    Dr Rebecca Ashfield, Senior Project Manager, The Jenner Institute, University of Oxford

  • 09.15 – 10.15: Prelude to human and veterinary vaccinology: scientific, manufacturing and regulatory synergies
    Prof Adrian Hill, Director, The Jenner Institute, University of Oxford

  • 10.15 – 11.15: An overview of veterinary vaccines
    Dr Bryan Charleston, Head of Livestock Viral Diseases Programme, The Pirbright Institute & Investigator, The Jenner Institute, University of Oxford

  • 11.15 – 11.45: Coffee break

  • 11:45 – 12:45: The success of childhood vaccination - the expanded programme of immunisation (EPI)
    Dr Vasee Moorthy, Team Leader, Vaccine Development, Department of Immunization, Vaccines & Biologicals, World Health Organisation

  • 12.45 – 14.00: Lunch

  • 14.00 – 15.00: Vaccines, herd immunity and eradication programme
    Prof Paul Fine, Professor of Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine

  • 15.00 – 15.30: Coffee break

  • 15.30 – 16.30: Rational development of foot-and-mouth disease virus vaccines
    Dr Bryan Charleston, Head of Livestock Viral Diseases Programme, The Pirbright Institute & Investigator, The Jenner Institute, University of Oxford

  • 16.30 – 17.30: Vaccines for enteric pathogens: Success stories and future challenges
    Prof David Lewis, Professor of Vaccine Immunology, University of Surrey

Day 2

  • 09.00 – 10.30: Immune defence mechanisms in humans
    Dr Teresa Lambe, Senior Immunologist, Influenza Vaccine Group, The Jenner Institute, University of Oxford

  • 10.30 – 11.00: Coffee break

  • 11.00 – 12.00: Immune defence mechanisms in animals
    Dr Jayne Hope, Senior Research Fellow, The Roslin Institute, University of Edinburgh

  • 12.00 – 13.00: Natural infections of livestock and animals as models for human diseases
    Dr Geraldine Taylor, Head of Veterinary Vaccines, The Pirbright Institute

  • 13.00 – 14.00: Lunch

  • 14.00 – 15.00: Malaria vaccines
    Prof Adrian Hill, Director, The Jenner Institute, University of Oxford

  • 15.00 – 16.00: Lessons from Marek's disease
    Prof Venugopal Nair, Head of Viral Oncogenesis Group, The Pirbright Institute and Investigator, The Jenner Institute, University of Oxford

  • 16.00 – 16.30: Coffee break

  • 16.30 – 17.30: Ebola vaccines
    Prof Adrian Hill, Director, The Jenner Institute, University of Oxford

  • 17.45 - Walking Tour of Oxford

Day 3

  • 09.00 – 10.00: HIV vaccines - dealing with HIV diversity
    Dr Lucy Dorrell, Senior Clinical Lecturer, Honorary Consultant in GUM/HIV, The Jenner Institute, University of Oxford
  • 10.00 – 11.00: Global progress in TB Vaccine development
    Prof Helen McShane, Professor of Vaccinology, Wellcome Senior Fellow, PI, Head of TB vaccines group, The Jenner Institute, University of Oxford
  • 11.00 – 11.30: Coffee break
  • 11:30 – 12.30: Vaccine adjuvants: definitions and historical perspectives
    Dr Nicolas Collin Head of The Vaccine Formulation Laboratory, University of Lausanne (UNIL)
  • 12:30 – 14.00: Lunch
  • 14:00 – 15.00: Adjuvants for diseases of low income countries and case studies
    Dr Nicolas Collin Head of The Vaccine Formulation Laboratory, University of Lausanne (UNIL)
  • 15.00 – 15.30: Coffee break
  • 15.30 – 16.30: Antigen screening/selection processes
    Dr Simon Draper, Investigator, Blood-stage Malaria Group, The Jenner Institute, University of Oxford
  • 16.30 – 17.15: Vaccinology interactive session

Day 4

  • 09.00 – 10.30: The immunobiology of conjugate vaccines for childhood disease
    Dominic Kelly, BRC Consultant in paediatrics and Vaccinology, University of Oxford
  • 10.30 – 11.00: Coffee break
  • 11.00 – 12.00: HPV: epidemiology and vaccines
    Dr Margaret Stanley, Department of Pathology, University of Cambridge
  • 12.00 – 13.00: Vaccines against addiction and chronic diseases
    Dr Martin F Bachmann, Professor of Immunology, The Jenner Institute, University of Oxford
  • 13.00 – 14.15: Lunch
  • 14.15 – 15.15: Human and avian influenza
    Prof Sarah Gilbert, Professor of Vaccinology, Programme Director for Wellcome Trust Strategic Award on Human and Veterinary Vaccine Development, The Jenner Institute, University of Oxford
  • 15.15 – 15.45: Coffee break
  • 15.45 – 16.45: Theileria vaccination
    Dr Simon Graham, Group Leader, Livestock Viral Disease Programme, The Pirbright Institute and Senior Lecturer, School of Veterinary Medicine, University of Surrey
  • 16.45 - 17.30: Vaccinology Case Studies

Day 5

  • 09.00 - 10.00: Vaccine design: Lessons from Respiratory Syncytial Virus (RSV) in cattle and Africa Swine Fever (ASF) in Pigs
    Dr Geraldine Taylor, Head of Veterinary Vaccines, The Pirbright Institute

  • 10.00 – 11.00: Bluetongue and African horse sickness vaccination
    Prof Peter Mertens, Head of Vector-borne Viral Diseases Programme, The Pirbright Institute

  • 11.00 – 11.30: Coffee break

  • 11.30 – 12.45: Ethical issues essential to the successful development of vaccines
    Dr Mark Sheehan, Biomedical Research Centre Ethics Fellow, The Ethox Centre and James Martin Research Fellow, Institute for Science & Ethics, University of Oxford

  • 12.45 – 14.00: Lunch

  • 14:00 – 15.00: Vaccines biodefence (plague, botulinum, anthrax)
    Dr Diane Williamson, Senior Scientist, Defence Science and Technology Laboratory (DSTL)

  • 15.00: Refreshments available in teaching room

  • 15.00 – 16.00: Economics of immunisations: key challenges and opportunities for innovative financing
    Dr Andrew Farlow, Research Fellow, Department of Economics, and Senior Research Fellow, Department of Zoology, University of Oxford

  • 16.00: Discussion, concluding comments and closure of the course

Course content

Please note the course content detailed above may be subject to change.

"Funding for the original course development was provided by the BBSRC, through the Modular Training for Industry Programme, and the MRC".

Certification

Participants who attend the full course will receive a Certificate of Attendance. The sample shown is an illustration only and the wording will reflect the course and dates attended.

Accommodation

Accommodation is available at the Rewley House Residential Centre, within the Department for Continuing Education, in central Oxford. The comfortable, en-suite, study-bedrooms have been rated as 4-Star Campus accommodation under the Quality In Tourism scheme, and come with tea- and coffee-making facilities, free Wi-Fi access and Freeview TV. Guests can take advantage of the excellent dining facilities and common room bar, where they may relax and network with others on the programme.

Fees

Standard course fee: £1725.00

Payment

Student Discounts
On this course we offer a 10% discount to students in full-time higher education. To apply at the discounted rate, please contact us for details:
email vaccinology@conted.ox.ac.uk or telephone: +44(0)1865 286958

 

We offer several payment options:

Pay immediately online by credit or debit card

Click the “book now” button on this webpage to pay online with a credit or debit card

Pay later with your preferred payment method

Send a completed application form to the course administrator by e-mail or post, and choose:

  • Request an invoice
  • BACS payment
  • Cheque payment
  • Credit or debit card payment. Please do not send card details via email

 

Fees include course materials, tuition, refreshments and lunches, as well as a walking tour of Oxford. The price does not include accommodation.

All courses are VAT exempt.

Tutors

Prof Adrian Hill

Director

Director, The Jenner Institute, University of Oxford

Principal areas of research: Malaria vaccines, vectored vaccine development, immunogenetics of infectious disease susceptibility

Adrian Hill trained in medicine at Trinity College Dublin and the University of Oxford, qualifying in 1982. He undertook a DPhil with Sir David Weatherall and John Clegg at the MRC Molecular Haematology unit on the molecular population genetics of thalassaemia in Pacific Islanders. Following further clinical posts in London he returned to the newly opened Institute of Molecular Medicine in 1988 to study genetic susceptibility to malaria as a Wellcome Trust Senior Fellow. In 1995 he was awarded a Wellcome Trust Principal Research Fellowship and in 1996 the title of Professor of Human Genetics. He participated in the founding of the Wellcome Trust Centre for Human Genetics in 1994, and in 2003 co-founded the Oxford Centre for Clinical Vaccinology and Tropical Medicine, which he now chairs. In 2004 he participated in the restructuring of the Edward Jenner Institute for Vaccine Research and in 2005 was appointed director of the new Jenner Institute. He is a Fellow of the Royal College of Physicians, of Magdalen College, Oxford, and of the UK Academy of Medical Sciences.

Dr Rebecca Ashfield

Speaker

Senior Project Manager, The Jenner Institute, University of Oxford

Rebecca Ashfield gained a first degree in Biochemistry and DPhil in molecular biology, both from Oxford University.

She carried out post-doctoral research into regulation of gene transcription and Type II Diabetes, and was awarded junior research fellowships by Magdalen College and Worcester College Oxford.

Dr Ashfield then worked for 12 years as a project and collaborations manager at Immunocore Ltd, a biotechnology company making protein therapeutics for cancer immunotherapy, and joined the Jenner Institute in 2013 as a senior project manager for pre-clinical malaria, working with Professor Adrian Hill.

Dr Martin Bachmann

Speaker

Professor of Immunology, The Jenner Instiute, University of Oxford

Martin F. Bachmann is currently Professor of Immunology at the Jenner Instiute, University of Oxford.

Martin F. Bachmann, PhD in molecular biology was formerly the Chief Executive Officer of Saiba. Dr. Bachmann received his PhD in 1995 at the Institute for Experimental Immunology Zurich in the laboratories of Prof. Zinkernagel and Prof. Hengartner. He joined Cytos from the Basel Institute for Immunology where he was a Member in October 1999. He has published over 100 articles in internationally renowned scientific journals. His achievements were honored with two ETH Medals (1991 and 1995) and the Pfizer Prize for Immunology (1998) and he is laureate of the 'Swiss Technology Award 2004'.

Dr Bryan Charleston

Speaker

Head of the Livestock Viral Diseases programme, The Pirbright Institute and Investigator, Jenner Institute, University of Oxford

Dr Charleston obtained a BVetMed from the Royal Veterinary College, University of London, UK in 1982. After a period of time in Large Animal Practice, studied for a Masters degree in Molecular Biology at University College London in 1988, then a PhD degree, as a Wellcome Trust Scholar, from the University of London, UK, in 1991. He then carried out postdoctoral research, as a Wellcome Trust Post-doctoral fellow, at the Royal Veterinary College and the Babraham Institute, Cambridge for three years. He joined the Institute for Animal Health in 1994 and focussed on studies of the immune response to viral infections in cattle. In addition, he has provided advice and expertise on the design of infectious disease challenge models for a wide range of pathogens in important agricultural species. His research groups are based at the Compton site near Oxford and the Pirbright site in Surrey; the group’s efforts are focused on understanding the immune response to Foot-and–Mouth disease virus in cattle to develop novel vaccines.

Dr Nicolas Collin

Speaker

Lead, Vaccine Formulation Laboratory, University of Lausanne

Nicolas Collin holds a Doctorate in Veterinary Medicine from the National Veterinary School of Toulouse, France, and a PhD in Molecular Microbiology from University Paul Sabatier of Toulouse. He worked as project leader in the biotech industry (Transgene) then did a visiting fellowship at the National Institutes of Health (NIH) in Washington DC, USA, where he worked on vaccines against canine Leishmaniasis.

In 2008, Dr Collin joined the World Health Organization Headquarters (Geneva, Switzerland) as technical officer on influenza vaccines. During the pandemic influenza of 2009, he served as coordinator of the WHO pandemic H1N1 vaccine task force.

Dr Collin has been leading the Vaccine Formulation Laboratory (VFL) at University of Lausanne since its inception in 2010. Created under the auspices of WHO, the VFL is a platform providing access to adjuvants and formulation expertise for the scientific community, with a special focus to the public sector and Under-Resourced countries.

Dr Lucy Dorrell

Speaker

Senior Clinical Lecturer, Honorary Consultant in GUM/HIV, The Jenner Institute, University of Oxford

Lucy Dorrell obtained a Bachelor of Medicine from the University of Southampton in 1988. After junior hospital posts during which she obtained MRCP, she began her research career in 1993 as a Clinical Research Fellow in Communicable Diseases and Genitourinary Medicine at Imperial College, London with Professor Jonathan Weber.

She was awarded a DM degree in 1998 from the University of Southampton for her research into antigen-presenting cell function in HIV infection. She was subsequently awarded an MRC Clinical Training Fellowship to study immunological mechanisms of resistance to HIV-1 and HIV-2 under Professor Sarah Rowland-Jones at MRC Laboratories, The Gambia and at the Weatherall Institute of Molecular Medicine. In 2000 she was awarded an MRC Clinician Scientist Fellowship, which she took up in 2002 after completing clinical specialist training and obtaining a CCST in HIV/GUM.

With Professor Andrew McMichael she set up a programme of translational research evaluating therapeutic immunisation in HIV-1 infection with novel DNA and modified vaccinia virus Ankara-vectored HIV-1 vaccines developed at MRC Human Immunology Unit. She was awarded a HEFCE Clinical Senior Lectureship in 2007.

Her research team is conducting further clinical therapeutic vaccination studies while also investigating mechanisms which determine success or failure of host immune control of HIV.

Dr Simon Draper

Speaker

Investigator, Blood-stage Malaria Group, The Jenner Institute, University of Oxford

My undergraduate degree was in Molecular and Cellular Biochemistry at Trinity College, Oxford University, and included research projects at the Institute for Hormone and Fertility Research in Hamburg, Germany, and at the Weatherall Institute of Molecular Medicine in Oxford with Dr Chris Norbury. I subsequently joined Prof Adrian Hill’s research group in the Nuffield Department of Medicine at Oxford University. The subject of my DPhil thesis was the development of new antibody-inducing vectored vaccines against the blood-stage of malaria infection. I have since stayed on at the Jenner Institute, first as a Junior Research Fellow of Merton College, and subsequently as a MRC Career Development Fellow. The aim of my work is to develop and translate new vaccine candidates for malaria into proof-of-concept human clinical studies. My group has a particular interest in optimising antibody induction by vectored vaccines, as well as better understanding vaccine-induced immunity to the blood- and mosquito-stages of malaria infection.

Dr Andrew Farlow

Speaker

Research Fellow, Department of Economics and Senior Research Fellow, Department of Zoology, University of Oxford

Andrew Farlow is a Research Fellow in Economics, Department of Economics, and Senior Research Fellow, Department of Zoology, University of Oxford. He is co-PI on Oxford’s new Vaccine Design Institute, with responsibilities for its ‘Vaccine Health Economics’ component, and he is part of the Oxford contingency of the new International Research Consortium on Dengue Risk Assessment, Management and Surveillance (IDAMS). His research interests span the economics of pharmaceutical R&D; measurement of the socioeconomic impact of health interventions (drugs, vaccines, diagnostics, and vector control); global health funding; affordable innovation and technology transfer; application of financial and risk management tools to global health analysis; and market, pricing, launch, and delivery strategies, especially in resource-poor settings. He has advised a wide variety of public and private sector organizations including: WHO; Bill and Melinda Gates Foundation; UK Department for International Development; Aeras TB Vaccine Foundation; TB Alliance; Policy Cures; Médecins Sans Frontières; World Economic Forum; Dalberg, Global Development Advisors; Results for Development Institute; Global Alliance for Vaccines and Immunization; Office of Health Economics, London; UK Treasury; World Bank; Malaria Vaccine Initiative; the UK’s Joint Committee on Vaccines and Immunizations, etc. He is a member of the Stop TB Partnership Working Group on New TB Vaccines: Task Force on Economics and Product Profiles (WHO, Bill and Melinda Gates Foundation, Aeras Global TB Vaccine Foundation). He teaches Vaccine Deployment and Policies for the Vaccinology module of the Oxford MSc in Global Health Science. He was educated at the Universities of Cambridge and Oxford.

Prof Paul Fine

Speaker

Professor of Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine

Paul Fine trained originally in zoology, veterinary medicine, parasitology and epidemiology, and joined the staff of LSHTM in 1976. His major methodological interests have been in infection dynamics, family studies, genetics, and the evaluation of vaccines (efficacy, adverse reactions and impact), applied to a variety of infections. Much of his earlier work concentrated upon vertical (from parent to progeny) transmission of infections and upon measles and pertussis in the UK. He directed a large epidemiological research programme (the "Karonga Prevention Study") in Malawi from 1978-2006, concentrating at first upon leprosy, then tuberculosis, and ultimately HIV, and including demographic surveillance, vaccine evaluation, and studies of other infections in a rural population in northern Malawi.

In recent years he has been involved in a variety of vaccine related issues, including evaluation of the transmissibility of oral polio vaccine virus and its implications for the global polio eradication programme, the optimisation of infant vaccination schedules, and methods to evaluate the field effectiveness of foot and mouth vaccines in Turkey and Iran.

Prof Sarah Gilbert

Speaker

Professor of Vaccinology, Programme Director for Wellcome Trust Strategic Award on Human and Veterinary Vaccine Development, The Jenner Institute, University of Oxford

After a first degree in Biological Sciences at the University of East Anglia, specializing in Microbiology, and a PhD on lipid metabolism in the Biochemistry Department at the University of Hull, Prof Gilbert worked on pentose metabolism in brewing yeasts at the Brewing Research Foundation in Surrey. This led to a research post at the Leicester Biocentre, using molecular biology techniques to study heterologous protein expression in yeast. Prof Gilbert spent four years at Delta Biotechnology in Nottingham, working on production of recombinant human blood proteins in yeast before moving to Adrian Hill’s group at the University of Oxford in 1994.

Prof Gilbert’s chief research interest is the development of vaccines that work by inducing strong and protective T cell responses. This has included work on DNA vaccines and virus-like protein particles carrying multiple T cell epitopes on their surface, as well as the viral vaccine vectors Modified Vaccinia virus Ankara (MVA), fowlpox and adenovirus.

Following the discovery that heterologous prime-boost immunisation, in which the same antigen is delivered in first one vector and then another, is highly immunogenic in pre-clinical studies, she designed antigen inserts for, and produced DNA, MVA and fowlpox vaccines which were then manufactured for clinical trials in both the malaria and tuberculosis vaccine clinical programmes.

More recently Prof Gilbert has begun to apply the same principles of vaccine development, pre-clinical and clinical testing to new vaccines against influenza. The currently available ‘flu vaccines work by inducing antibodies to highly variable surface proteins of the virus, and slightly different versions have to be manufactured each year to keep up with changes in the virus. However the internal proteins of the ‘flu virus, which are produced inside infected cells, are well conserved, not only from one year to the next, but also between seasonal ‘flu viruses and those normally found only in avian species. Using these antigens, it should be possible to make a vaccine that protects against all subtypes of influenza, and ultimately, to stop a new pandemic in its tracks.

Dr Jayne Hope

Speaker

Senior Research Fellow, The Roslin Institute, University of Edinburgh

Dr Hope obtained a BSc (Hons) degree in Biological Sciences (Microbiology) from the University of Birmingham, UK in 1991, and a PhD degree from the University of Manchester, UK, in 1994. She then carried out postdoctoral research at the University of Manchester (1994-1996) and Kings College School of Medicine and Dentistry (1996-1997). Between 1997 and 2011 Dr Hope worked at the Institute for Animal Health carrying out research into bovine tuberculosis (TB) and immune mechanisms that lead to protective immunity. Dr Hope moved to The Roslin Institute in August 2011.

Dr Dominic Kelly

Speaker

BRC Consultant in Paediatrics and Vaccinology, University of Oxford

Dr. Kelly is a BRC funded consultant in paediatrics and vaccinology. He divides his time between working in general paediatrics and paediatric infectious disease at the Children’s Hospital in Oxford and vaccine related research within the Oxford Vaccine Group. His research interests are centred around vaccines and vaccine preventable disease in childhood and include the immunology of B-cell responses to vaccines in childhood, B-cell receptor genetics as a tool for understanding immune responses, pneumococcal conjugate vaccines and the epidemiology of invasive bacterial disease and pneumonia in Nepal.

Dr Teresa Lambe

Speaker

Senior Pre-Clinical Scientist
Oxford Martin Programme on Vaccines, University of Oxford

During my PhD studies of mammary gland development and cancer biology, it became apparent that, in many ways, cancer can be thought of as a failure of proper immunological surveillance. I consequently focused on understanding the adaptive immune response, through the use of transgenic models of disease and ENU mutagenesis.

Through these works, I have delineated adaptive immune function underpinning human disease conditions, particularly focussing on the role for T & B lymphocytes. Through my position as Pre-Clinical Immunologist at the Jenner Institute I can now apply this knowledge to rationally design and augment one of society's most powerful tool against infectious disease; vaccines.

Prof David Lewis

Speaker

Professor of Vaccine Immunology, University of Surrey

David Lewis serves as Professor of Vaccine Immunology in the Faculty of Medicine & Healthcare Sciences at the University of Surrey. He has led a number of high profile vaccine projects including those to address the Human Papilloma Virus (Cervical Cancer vaccine), Shigella dysentery, typhoid, tuberculosis, BCG and HIV, at St. George's for over 20 years and now at the University of Surrey. He has also worked on novel delivery technologies including nasal, oral, sublingual and cervio-vaginal administration routes.

He serves as an advisor to Pevion Biotech AG, and Chairs DSMB for Novartis Vaccines & Diagnostics and Lundbeck. He is a member of the Scientific Advisory Committee on Genetic Modification (Contained Use).

Prof Helen McShane

Speaker

Professor of Vaccinology, Wellcome Senior Fellow, PI, Head of TB vaccines group, The Jenner Institute, University of Oxford

Principal areas of research: MVA85A Tuberculosis Vaccine (BCG booster vaccine).

Helen McShane obtained an intercalated BSc in 1988, and then a degree in medicine in 1991; both from the University of London. After junior hospital posts during which she obtained MRCP in 1994, she worked as a registrar in Infectious Diseases and HIV/GU medicine for 3 years. She then began a PhD with Adrian Hill in 1997, and was awarded a PhD in 2001, also from the University of London. In 2001 she was awarded a Wellcome Clinician Scientist Fellowship to establish a translational programme of vaccine research evaluating new TB vaccines in the clinic. This fellowship also allowed her to complete her clinical training and she was awarded a CCST in HIV and GU Medicine in 2003. In 2005, she was awarded a Wellcome Senior Clinical Fellowship, which she took up in 2006. Her research team continues with the programme of translational vaccinology, and is involved in developing new assays for monitoring vaccination induced cellular immune responses, developing a BCG challenge model in humans and the aerosol delivery of vaccines.

Prof Peter Mertens

Speaker

Head of Vector-borne Viral Diseases Programme, The Pirbright Institute

Dr Vasee Moorthy

Speaker

Technical Officer, Department of Immunization, Vaccines & Biologicals, World Health Organisation

Dr Vasee Moorthy serves as the malaria vaccine focal point for WHO in Geneva. He acts as secretariat for two WHO malaria vaccine advisory committees —MALVAC and JTEG, which provide recommendations to WHO about malaria vaccine research and development and clinical evaluation. He facilitates the global Malaria Vaccine Funders Group and works to find synergies among funders to accelerate development of malaria vaccines for developing countries. His role includes coordination of development of global norms and standards within malaria vaccine development. He has previously served as senior program officer in clinical vaccinology at the PATH Malaria Vaccine Initiative.

Dr Moorthy has 15 years of experience covering clinical infectious diseases and tropical medicine, five years based in sub-Saharan Africa conducting malaria vaccine field trials and clinical malaria research. He serves on various Data and Safety Monitoring Boards and Scientific Advisory Committees, is an editorial board member of PLoS ONE, reviews articles from academic journals, including The Lancet and Lancet Infectious Diseases. He holds a BA (first class) in Natural Sciences from the University of Cambridge, a clinical medicine degree from the University of Oxford, and a PhD in malaria immunology from the Institute of Molecular Medicine, Oxford.

Prof Venugopal Nair

Speaker

Head of Viral Oncogenesis Group, The Pirbright Institute and Investigator, The Jenner Institute, University of Oxford

Principal areas of research: virus-induced cancers, molecular mechanisms of oncogenesis, role of virus- and host-encoded microRNAs in oncogenesis, novel antiviral vaccines.

Prof Venugopal Nair obtained the Bachelors Degree in Veterinary & Animal Sciences from the Kerala Agricultural University, Trichur, India in 1976. After obtaining a PhD in Veterinary Medicine from the Tamil Nadu Agricultural University, Chennai, India in 1987, he started his research career as a post-doctoral scientist at the Indian Institute of Science, Bangalore. Dr Nair joined Dr Ernie Gould’s group at the Institute of Virology & Environmental Microbiology, Oxford as postdoctoral research fellow in 1989, where he carried out extensive research until 1994 on the molecular biology of arthropod-borne flaviviruses.

Dr Nair moved to the Institute for Animal Health in 1994 to join Dr Jim Payne’s group to work on avian oncogenic viruses. He became the Head of the Viral Oncogenesis group following Dr. Payne’s retirement, and since been leading the research on the pathogenesis of avian oncogenic viruses such as Marek’s disease. Dr. Nair is the designated expert of the OIE (Office International des Epizooties) Reference Centre on Marek’s disease and was the Chairman of the organizing committee of the 7th International Marek’s Disease Symposium in Oxford in 2004. He is also a Visiting Professor at Imperial College London since 2005, and is a member of the Board of Editors of Avian Pathology. Prof. Nair became a Jenner Investigator in January 2007.

Dr Mark Sheehan

Speaker

Biomedical Research Centre Ethics Fellow, The Ethox Centre and James Martin Research Fellow, Institute for Science & Ethics, University of Oxford

Mark Sheehan is Oxford Biomedical Research Centre (BRC) Ethics Fellow at the Ethox Centre and a James Martin Research Fellow in the Institute for Science and Ethics. He received his PhD in Philosophy from The City University of New York, where his PhD thesis was on the nature of moral judgements. Prior to his PhD, he received an MA (Hons) and a BA (Hons)/BSc from the University of Melbourne. Prior to coming to Oxford he was a lecturer in the Centre for Professional Ethics at Keele University, Ethics Fellow at the Mt. Sinai Medical School, New York and Adjunct Lecturer in the Philosophy Department at The City College of New York.

As BRC Ethics Fellow, Mark is involved in Research Ethics and Patient and Public Involvement (PPI) across the Oxford NIHR BRC themes. This involvement includes discussions with researchers about research ethics issues in their work, collaborating on research proposals with ethical components and conducting research on issues in research ethics, ethics generally and PPI that engage with the research themes within the BRC. As a member of the Institute for Science and Ethics, Mark is involved in research identifying and critically analysing ethical issues and problems arising in stem cell science, cloning, artificial reproduction and genetics.

The Institute is part of the Oxford Martin School and so he is also involved in a number of collaborations with other parts of the School. Mark has set up and teaches (with the considerable help of colleagues) a series of sessions on research ethics aimed at researchers in the Medical Sciences Division and at the Oxford Radcliffe Hospital. From Hilary term 2011 he will lead (again with the help of colleagues) a seminar series in the Centre for Doctoral Training in Healthcare Innovation in the Institute for Biomedical engineering on the ethics and biotechnology. He also teaches Medical Ethics and Law to the Graduate Entry Medical students at the Medical School and lectures on the Medical Law and Ethics course in the Law School. He has published in such journals as the Journal of Applied Philosophy, the Journal of Medical Ethics, the Cambridge Quarterly on Healthcare Ethics and the American Journal of Bioethics. With colleagues from the Centre for Professional Ethics at Keele University, he has just completed an EU-funded textbook on research ethics. He is a member of the Advisory Group for National Specialised Services (AGNSS) and the Thames Valley Priorities Forum (MOBBB) for the South Central Strategic Health Authority. He also sits on the University’s Social Sciences and Humanities Inter-Divisional Research Ethics Committee and is an external member of the Goldsmith’s Research Ethics Committee. He is a Senior Research Fellow in Philosophy at St. Benet’s Hall.

Current Research Themes: 1.Research Ethics and Governance 2.Ethics and Reproductive Technologies 3.Ethical issues in Resource Allocation 4.Commercialisation and Health 5.Methodology in Applied Ethics and Bioethics

Dr Geraldine Taylor

Speaker

Head of Vaccinology, The Pirbright Institute

After graduating from Liverpool University with a BSc (Hons) in Medical Microbiology, Geraldine Taylor obtained an MRC Scholarship for Training in Research Methods in the Division of Communicable Diseases, MRC Clinical Research Centre, Harrow, Middlesex. She was awarded a PhD from the University of London in 1975 for her work on the role of T cells in mycoplasma infections. She then took up an appointment at the Institute for Animal Health, Compton, investigating the role of the immune response in respiratory mycoplasma infections. After spending a sabbatical at the University of Alabama in Birmingham, Alabama, USA, she returned to the Institute for Animal Health (now The Pirbright Institute) and established a group working on the immunology of respiratory syncytial virus (RSV) infections. Her research team continues with research on RSV with the aim of developing safe and effective vaccines, and is also involved in the development of a vaccine against African Swine Fever.

Dr Diane Williamson

Speaker

Senior Scientist, Defence Science and Technology Laboratory (DSTL)

Dr Williamson is an experienced immunologist, working in a microbiological context. She has a track record of successful research and has had scientific input to a range of R&D projects, initially in the veterinary vaccine field during her employment with the Agricultural and Food Research Council in the UK. More recently, she has worked in the biodefence field, particularly on the R&D of new recombinant vaccines for plague and anthrax, being involved in both programmes from initiation to clinical trial. Currently she is a Principal Scientist at DSTL Porton Down, contributing to the technical management of a number of projects towards the development of vaccines and therapies for serious human pathogens , with practical input to others. She has authored over 120 peer-reviewed papers and supervised 12 PhD students to completion.

Course aims

This training course will provide students with:

  • An overview of the field of human and veterinary vaccinology, from Edward Jenner to modern day vaccines.
  • An understanding of the immune system and immune mechanisms needed to provide protection from disease.
  • An understanding of the recent advances that have been made in the vaccine field and appreciation of the impact of molecular immunology and pathogen genomics on vaccine development.
  • An overview of the molecular methods used for the design and construction of vaccines.
  • An appreciation of the importance of pre-clinical testing and the many factors involved in the selection of animal models.
  • The ability to understand and interpret the bioassays used to measure vaccine immunogenicity and to understand how immunogenicity correlates with protection.
  • An understanding of the role of veterinary vaccines in animal heath, animal welfare, environmental protection and public health.
  • An understanding of the vaccine development pathway - from bench to market.
  • An overview of the ethical issues surrounding vaccine development and deployment.

 

Application

If you would like to discuss your application or any part of the application process before applying, please contact:
Course Administrator
Tel: +44 (0)1865 286958
Email: vaccinology@conted.ox.ac.uk

Terms and conditions

For applicants and students on this course

Sources of funding

Find information on the different ways in which we may be able to help to support you financially whilst you are studying with us.

Level and demands

Vaccinology is a cross-disciplinary subject and the most exciting developments in vaccinology have occurred when people from diverse research, business and medical backgrounds have used their skills to collectively tackle problems in vaccine design, manufacture and distribution.

Our course participants will therefore reflect the diversity of the subject and be from business, academic, clinical and veterinary backgrounds. The course will be of particular interest to research scientists, programme managers, clinical trial coordinators, nurses, physicians and veterinarians. The course will be accessible to people already working in the field or to those who wish to enter the field.

People from the following organisations and companies have attended the Oxford Vaccinology Programme:

Baxter BioScience, Baxter Innovations GmbH, Boehringer Ingelheim Animal Health GmbH, Centre for Clinical Vaccinology and Tropical Medicine (University of Oxford), Clinical Biomanufacturing Facility (University of Oxford), Commission on Human Medicines, Cumbria and Lancashire Health Protection Unit, Datamonitor, Department of Paediatrics (University of Oxford), Division of Public Health and Primary Health Care (Oxford), Drug Delivery Solutions, European Medicines Agency (EMEA), Emergent BioSolutions Inc, Federal Ministry of Animal Resources and Fisheries, Genecom, Glide Pharma, ICON Clinical Research, IDT Biologika GmbH, Imaxio, Inocul8, Institute for Animal Health (IAH), Irsicaixa, Laboritorios Leti, S.L., London School of Hygiene and Tropical Medicine, Medicago R&D, MHRA, Moredun Research Institute, Novartis, Nuffield Department of Clinical Medicine (University of Oxford), Oxford Vaccine Group, PATH Malaria Vaccine Initiative (MVI), Pfizer Ltd, Sagittarius IP, Solvay Biologicals, Solvay Pharmaceuticals Inc, Statens Serum Institut, Subiaco Associates Ltd, The Jenner Institute (University of Oxford), Tropical Medicine (University of Oxford), Vaccibody AS, Veterinary Laboratories Agency, Wellcome Trust Centre for Human Genetics, World Health Organisation, Wyeth

If you're uncertain whether this course is suitable for your requirements, please email us with any questions you may have.